(Press-News.org) Contact information: Irene Sege
irene.sege@childrens.harvard.edu
617-919-3110
Dana-Farber Cancer Institute
Antipsychotic drug exhibits cancer-fighting properties
In zebrafish model, perphenazine activates therapeutic pathway for intractable leukemia, may hold promise for other tumors
BOSTON, Jan. 9, 2014 - In a prime example of finding new uses for older drugs, studies in zebrafish show that a 50-year-old antipsychotic medication called perphenazine can actively combat the cells of a difficult-to-treat form of acute lymphoblastic leukemia (ALL). The drug works by turning on a cancer-suppressing enzyme called PP2A and causing malignant tumor cells to self-destruct.
The findings suggest that developing medications that activate PP2A, while avoiding perphenazine's psychotropic effects, could help clinicians make much-needed headway against T-cell ALL, and perhaps other tumors as well.
A study team led by Alejandro Gutierrez, MD, and A. Thomas Look, MD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and Jon Aster, MD, PhD, of Dana-Farber Cancer Institute and Brigham and Women's Hospital, reported the results Jan. 9 in the Journal of Clinical Investigation.
T-ALL is rarer and more aggressive than the B-cell form of ALL, and it has a relatively poor prognosis. Despite improvements in the treatments available, 20 percent of children and more than 50 percent of adults diagnosed with T-ALL succumb to it.
To identify possible new treatment options, Gutierrez, Look and their collaborators screened a library of 4,880 compounds—including FDA-approved drugs whose patents had expired, small molecules and natural products—in a model of T-ALL engineered using zebrafish.
Strategies that identify new uses for existing drugs have grown in popularity in recent years as a way of quickly developing new disease therapies. Zebrafish models are cost-effective platforms for rapidly conducting drug screens, as well as basic stem cell, genetic, cancer and developmental research.
"We wanted to see if there were drugs or known bioactive molecules that are active against T-ALL that hadn't been tested yet," Look explained. "There may be drugs available for other indications that could be readily repurposed if we can show activity."
One of the strongest hits in the zebrafish screen was the drug perphenazine. It is a member of the phenothiazines, a family of antipsychotic medications used for 50 years, because they can block dopamine receptors.
The team verified perphenazine's anti-leukemic potential in vitro in several mouse and human T-ALL cell lines. Biochemical studies indicated that perphenazine's anti-tumor activity is independent of its psychotropic activity, and that it attacks T-ALL cells by turning on PP2A.
The fact that perphenazine works by reactivating a protein shut down in cancer cells is itself novel in the drug development field.
"We rarely find potential drug molecules that activate an enzyme," Gutierrez explained. "Most new drugs deactivate some protein or signal that the cancer cell requires to survive. But, here, perphenazine is restoring the activity of PP2A in the T-ALL cell."
Gutierrez and Look, along with their collaborators, are now working to better understand the interactions between PP2A and perphenazine. They also want to search for or develop molecules that bind to and activate the enzyme more tightly and specifically to avoid perphenazine's psychiatric effects.
"The challenge is to use medicinal chemistry to develop new PP2A inhibitors similar to perphenazine and the other phenothiazines, but to dial down dopamine interactions and accentuate those with PP2A," Look said.
The researchers see future PP2A inhibitors not as magic bullets but as potentially important additions to the oncologist's arsenal when treating patients with T-ALL.
" T-ALL patients are often on the borderline between a long remission and a cure," Look said. "If we can push the leukemia cells a little harder, we may get more patients who are actually cured. In this way, PP2A inhibitors may, in combination with other drugs, make a real difference for patients."
It may be that the benefits of PP2A-activating drugs could extend beyond T-ALL. "The proteins that PP2A suppresses, such as Myc and Akt, are involved in many tumors," Look noted. "We are optimistic that PP2A activators will have quite broad activity against different kinds of cancer, and we're anxious to study the pathway in other malignancies as well."
###
This study was supported by the National Cancer Institute (grant numbers K08CA133103 and P01CA109901), the Leukemia and Lymphoma Society, the William Lawrence Blanche Hughes Foundation, the Bear Necessities Foundation, the Ligue Nationale contre le Cancer, Association Laurette Fugain, Institut National du Cancer (INCA), Universités Paris Diderot and Paris Sud, INSERM, CEA and Canceropole Ile de France, European Union's Seventh Framework Programme and the American Society of Hematology.
The Dana-Farber/Boston Children's Cancer and Blood Disorders Center brings together two internationally known research and teaching institutions that have provided comprehensive care for pediatric oncology and hematology patients since 1947. The Harvard Medical School affiliates share a clinical staff that delivers inpatient care at Boston Children's Hospital and outpatient care at the Dana-Farber Cancer Institute's Jimmy Fund Clinic. Dana-Farber/Boston Children's brings the results of its pioneering research and clinical trials to patients' bedsides through five clinical centers: the Blood Disorders Center, the Brain Tumor Center, the Hematologic Malignancies Center, the Solid Tumors Center, and the Stem Cell Transplant Center.
Antipsychotic drug exhibits cancer-fighting properties
In zebrafish model, perphenazine activates therapeutic pathway for intractable leukemia, may hold promise for other tumors
2014-01-10
ELSE PRESS RELEASES FROM THIS DATE:
Some motor proteins cooperate better than others
2014-01-10
Some motor proteins cooperate better than others
Rice University researchers view competition, cooperation among motors in live cells
HOUSTON - (Jan. 9, 2014) - Rice University researchers have engineered cells to characterize how sensitively altering the cooperative functions of ...
ORNL-UT researchers invent 'sideways' approach to 2-D hybrid
2014-01-10
ORNL-UT researchers invent 'sideways' approach to 2-D hybrid
OAK RIDGE, Tenn., Jan. 9, 2014 -- Researchers at the Department of Energy's Oak Ridge National Laboratory and the University of Tennessee, Knoxville have pioneered a new technique for forming ...
Hubble probes interior of Tarantula Nebula
2014-01-10
Hubble probes interior of Tarantula Nebula
Like lifting a giant veil, the near-infrared vision of NASA's Hubble Space Telescope uncovers a dazzling new view deep inside the Tarantula Nebula. Hubble reveals a glittering treasure trove of more than ...
Hubble views stellar genesis in the Southern Pinwheel
2014-01-10
Hubble views stellar genesis in the Southern Pinwheel
A photogenic and favorite target for amateur astronomers, the full beauty of nearby barred spiral galaxy M83 is unveiled in all of its glory in this Hubble Space Telescope mosaic image. The ...
Novel biomarker approach suggests new avenues to improve schizophrenia disease management
2014-01-10
Novel biomarker approach suggests new avenues to improve schizophrenia disease management
Environmental effects of events such as oxygen deprivation and infections may be preserved as markers in blood that are associated to schizophrenia, according to an ...
Stem cells injected into nerve guide tubes repair injured peripheral nerve
2014-01-10
Stem cells injected into nerve guide tubes repair injured peripheral nerve
Putnam Valley, NY. (Jan. 9, 2014) – Using skin-derived stem cells (SDSCs) and a previously developed collagen tube designed to successfully bridge gaps in injured ...
Are you listening? Kids' ear infections cost health care system nearly $3 billion a year
2014-01-10
Are you listening? Kids' ear infections cost health care system nearly $3 billion a year
Acute otitis media, or ear infection, is the most common ailment among kids of preschool age and younger in the U.S., primarily because these children ...
NIH-created toxin can kill HIV-infected cells that persist despite treatment
2014-01-10
NIH-created toxin can kill HIV-infected cells that persist despite treatment
Approach could potentially be part of future HIV cure strategy
A team including University of North Carolina and NIH scientists has demonstrated in ...
Researchers develop tool to determine individual risk of prostate cancer overdiagnosis
2014-01-10
Researchers develop tool to determine individual risk of prostate cancer overdiagnosis
Nomogram aims to enable informed decision-making and personalized treatment
SEATTLE - Studies have found that prostate cancer is overdiagnosed in up to 42 percent ...
Study: Athlete's first reaction in victory is dominance
2014-01-10
Study: Athlete's first reaction in victory is dominance
Body language, also called 'triumph,' stronger in victors from cultures that emphasize hierarchy
SAN FRANCISCO -- Upon victory, an athlete's initial and instinctive reaction is one that displays dominance ...
LAST 30 PRESS RELEASES:
Less intensive works best for agricultural soil
Arctic rivers project receives “national champion” designation from frontiers foundation
Computational biology paves the way for new ALS tests
Study offers new hope for babies born with opioid withdrawal syndrome
UT, Volkswagen Group of America celebrate research partnership
New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll
Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes
University of Cincinnati Cancer Center presents research at AACR 2025
Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025
AACR: Researchers share promising results from MD Anderson clinical trials
New research explains why our waistlines expand in middle age
Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker
Chips off the old block
Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia
Cutting the complexity from digital carpentry
Lung immune cell type “quietly” controls inflammation in COVID-19
Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
State and sociodemographic trends in US cigarette smoking with future projections
Young adults drive historic decline in smoking
NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
Chimpanzee stem cells offer new insights into early embryonic development
This injected protein-like polymer helps tissues heal after a heart attack
FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology
In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity
Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects
A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions
AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate
Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative
Structure dictates effectiveness, safety in nanomedicine
Mission accomplished for the “T2T” Hong Kong Bauhinia Genome Project
[Press-News.org] Antipsychotic drug exhibits cancer-fighting propertiesIn zebrafish model, perphenazine activates therapeutic pathway for intractable leukemia, may hold promise for other tumors